Scholar RockSRRK
About: Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
Employees: 196
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
548% more capital invested
Capital invested by funds: $696M [Q3] → $4.51B (+$3.81B) [Q4]
350% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 9 (+7) [Q4]
320% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 20
44% more call options, than puts
Call options by funds: $75.1M | Put options by funds: $52.2M
39% more funds holding
Funds holding: 160 [Q3] → 222 (+62) [Q4]
13% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 60
2.91% more ownership
Funds ownership: 108.55% [Q3] → 111.46% (+2.91%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for SRRK.
Financial journalist opinion









